Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis

Journal of Rheumatology

Volumn 23, Issue 10, 1996, Pages 1719-1724

  Yoshida, Tadashi ^a   Kameda, Hideto ^a   Ichikawa, Yoichi ^b   Tojo, Takeshi ^a   Homma, Mitsuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

lupus nephritis; prostanoid metabolism; thromboxane A2 synthetase inhibitor

Indexed keywords

INDOMETACIN; NAFAGREL; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; INDOMETHACIN; KIDNEY; LUPUS NEPHRITIS; MIDDLE AGED; PROSTAGLANDINS; TETRAHYDRONAPHTHALENES; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 0029827382     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kimberly RP, Gill JR, Bowden RE, et al.: Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 1978;89:336-41.
2. 2 production in patients with systemic lupus erythematosus. J Clin Invest 1985;76:1011-8.
3. Yoshida T, Kameda H, Akizuki M, et al.: Abnormal prostanoid metabolism in systemic lupus erythematosus with pulmonary hypertension. J Rheumatol 1994;21:2393-4.
4. Scharschmidt LA, Lianos AE, Dunn MJ, et al.: Arachidonate metabolites and the control of glomerular function. Fed Proc 1983;42:3058-63.
5. 2 in glomerulonephritis. J Pharmacol Exp Ther 1985;233:672-8.
6. Austin HA III, Muenz LR, Joyce KM, et al.: Prognostic factors in lupus nephritis. Contribution of renal histologic data Am J Med 1983;75:382-91.
7. Kasai Y: Assay Methods of Renal PG and TX and Problems, Prostaglandin, Kidney and Hard Tissues. Tokyo: Tokyo Kagaku Dojin, 1988:53.
8. Grizzle JE: The two-period change-over design and its use in clinical trials. Biometrics 1965;21:467-80.
9. 2 formation in the human circulation. Proc Natl Acad Sci USA 1986;83:5861-5.
10. Patorono C, Ciabattoni G, Filabozzi P, et al.: Drugs, prostaglandin and renal function. Adv Prostaglandin Thromboxane Leukot Res 1985;13:131-9.
11. Kelley VE, Ferretti A, Izui S, et al.: Effect of inhibitors of arachidonic acid metabolism on mitogenes in human lymphocytes: Possible role of thromboxanes and products of the lipoxygenase pathways. J Immunol 1983;134:1914-9.
12. Kelley VE, Sneve S, Musinski S, et al.: Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 1986;77:252-9.
13. Patorono C, Dunn MJ: The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
14. Pierucci A, Simonetti BM, Pecci G, et al.: Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New Engl J Med 1989;320:421-5.
15. Patrignani P, Filabozzi P, Catella F, et al.: Differential effects of dazoxiben, a selective thromboxane synthetase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism. J Pharm Exp Therapeutics 1983;228:472-7.
16. Zipser RD: Effects of selective inhibition of thromboxane synthesis on renal function in humans. Am J Physiol 1985;248:F753-6.
17. 2 synthetase inhibitor, DP-1904, decreases TNF-α secretion from monocytes and inhibits E-selectin and ICAM-1 expression on the endothelial cell surfaces. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 23. New York: Raven Press, 1995:423-5.